This company has been marked as potentially delisted and may not be actively trading. Audentes Therapeutics (BOLD) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesShort InterestTrendsBuy This Stock BOLD vs. PRQR, ACTU, DERM, ACIU, HURA, LXRX, KRRO, ALDX, LRMR, and LFVNShould you be buying Audentes Therapeutics stock or one of its competitors? The main competitors of Audentes Therapeutics include ProQR Therapeutics (PRQR), Actuate Therapeutics (ACTU), Journey Medical (DERM), AC Immune (ACIU), TuHURA Biosciences (HURA), Lexicon Pharmaceuticals (LXRX), Korro Bio (KRRO), Aldeyra Therapeutics (ALDX), Larimar Therapeutics (LRMR), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry. Audentes Therapeutics vs. ProQR Therapeutics Actuate Therapeutics Journey Medical AC Immune TuHURA Biosciences Lexicon Pharmaceuticals Korro Bio Aldeyra Therapeutics Larimar Therapeutics LifeVantage Audentes Therapeutics (NASDAQ:BOLD) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Does the media favor BOLD or PRQR? In the previous week, ProQR Therapeutics had 18 more articles in the media than Audentes Therapeutics. MarketBeat recorded 18 mentions for ProQR Therapeutics and 0 mentions for Audentes Therapeutics. ProQR Therapeutics' average media sentiment score of 0.68 beat Audentes Therapeutics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Audentes Therapeutics Neutral ProQR Therapeutics Positive Do analysts prefer BOLD or PRQR? ProQR Therapeutics has a consensus price target of $8.75, indicating a potential upside of 339.70%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Audentes Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Audentes Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the MarketBeat Community believe in BOLD or PRQR? Audentes Therapeutics received 132 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 69.12% of users gave Audentes Therapeutics an outperform vote while only 62.13% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformAudentes TherapeuticsOutperform Votes47069.12% Underperform Votes21030.88% ProQR TherapeuticsOutperform Votes33862.13% Underperform Votes20637.87% Which has higher valuation and earnings, BOLD or PRQR? ProQR Therapeutics has higher revenue and earnings than Audentes Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAudentes TherapeuticsN/AN/A-$49.43MN/AN/AProQR Therapeutics$18.91M11.08-$30.43M-$0.34-5.85 Is BOLD or PRQR more profitable? Audentes Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. ProQR Therapeutics' return on equity of -71.58% beat Audentes Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Audentes TherapeuticsN/A -321.10% -40.02% ProQR Therapeutics -134.31%-71.58%-19.70% Do institutionals and insiders believe in BOLD or PRQR? 32.7% of ProQR Therapeutics shares are held by institutional investors. 5.3% of Audentes Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryProQR Therapeutics beats Audentes Therapeutics on 12 of the 15 factors compared between the two stocks. Get Audentes Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLD vs. The Competition Export to ExcelMetricAudentes TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.60M$6.86B$5.56B$8.03BDividend YieldN/A2.90%5.36%4.23%P/E RatioN/A7.5422.8118.90Price / SalesN/A259.70406.35106.96Price / CashN/A65.8538.1834.62Price / BookN/A6.566.794.34Net Income-$49.43M$143.88M$3.23B$248.27M Audentes Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLDAudentes TherapeuticsN/A$1.60-30.4%N/A-82.9%$44.60MN/A0.00207News CoverageGap UpPRQRProQR Therapeutics2.9404 of 5 stars$1.72+11.4%$8.75+410.2%-1.0%$178.34M$18.91M-5.30180Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageACTUActuate TherapeuticsN/A$9.06+0.1%$20.50+126.3%N/A$176.28MN/A0.0010DERMJourney Medical2.6972 of 5 stars$7.51-0.9%$9.88+31.5%+90.5%$175.13M$56.13M-8.0690Short Interest ↑News CoverageACIUAC Immune2.2093 of 5 stars$1.70-0.3%$12.00+608.0%-28.0%$170.20M$27.31M-3.68140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsHURATuHURA BiosciencesN/A$3.86-2.7%$12.67+227.8%N/A$169.70MN/A0.00N/ALXRXLexicon Pharmaceuticals3.3265 of 5 stars$0.68-1.2%$3.67+439.2%-60.9%$167.44M$31.08M-0.91140Positive NewsKRROKorro Bio1.6086 of 5 stars$17.74+1.5%$114.63+546.1%-64.1%$163.13M$2.27M-1.8570Analyst UpgradeAnalyst RevisionNews CoveragePositive NewsALDXAldeyra Therapeutics2.2798 of 5 stars$2.69-2.4%$9.67+259.0%-32.5%$160.26MN/A-2.8615Short Interest ↑LRMRLarimar Therapeutics1.6968 of 5 stars$2.45+4.0%$19.63+702.7%-61.8%$157.13MN/A-2.1330Earnings ReportUpcoming EarningsOptions VolumeAnalyst RevisionNews CoverageLFVNLifeVantage4.1928 of 5 stars$12.40+2.1%$30.50+145.9%+81.3%$155.32M$212.15M22.10260Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies ProQR Therapeutics Competitors Actuate Therapeutics Competitors Journey Medical Competitors AC Immune Competitors TuHURA Biosciences Competitors Lexicon Pharmaceuticals Competitors Korro Bio Competitors Aldeyra Therapeutics Competitors Larimar Therapeutics Competitors LifeVantage Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLD) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Audentes Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Audentes Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
